Tiziana Life Sciences (NASDAQ:TLSA) Stock Rating Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen cut shares of Tiziana Life Sciences (NASDAQ:TLSA) from a sell rating to a strong sell rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.

Several other equities research analysts also recently commented on TLSA. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tiziana Life Sciences in a research report on Wednesday, August 26th. Zacks Research upgraded shares of Tiziana Life Sciences to a “hold” rating in a research report on Tuesday, July 14th. Finally, BTIG Research reaffirmed a “buy” rating on shares of Tiziana Life Sciences in a research note on Tuesday, September 22nd. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Tiziana Life Sciences currently has a consensus rating of “Hold”.

Tiziana Life Sciences Stock Performance

NASDAQ:TLSA opened at $1.12 on Friday. The stock’s 50-day moving average is $1.01 and its 200-day moving average is $1.18. Tiziana Life Sciences has a 1-year low of $0.76 and a 1-year high of $2.33.

Insiders Place Their Bets

In other news, CEO Ivor Elrifi purchased 237,616 shares of the stock in a transaction on Wednesday, August 5th. The stock was purchased at an average price of $1.00 per share, for a total transaction of $237,616.00. Following the acquisition, the chief executive officer owned 4,793,684 shares in the company, valued at $4,793,684. This trade represents a 5.22% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders have purchased 988,423 shares of company stock worth $985,909. Corporate insiders own 39.82% of the company’s stock.

Institutional Investors Weigh In On Tiziana Life Sciences

A hedge fund recently raised its stake in Tiziana Life Sciences stock. Zhang Financial LLC lifted its stake in shares of Tiziana Life Sciences Ltd (NASDAQ:TLSA) by 12.0% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 111,900 shares of the company’s stock after acquiring an additional 12,000 shares during the period. Zhang Financial LLC owned 0.09% of Tiziana Life Sciences worth $131,000 at the end of the most recent reporting period.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a clinical-stage biotechnology company developing therapeutics for neuroinflammatory and autoimmune diseases. The company’s lead product candidate is foralumab, a fully human monoclonal antibody that targets the CD3 receptor on T cells and is being developed in an intranasal formulation designed to modulate immune activity.

Tiziana has evaluated foralumab in clinical research involving non-active secondary progressive multiple sclerosis and has also investigated its potential in conditions involving neuroinflammation, including Alzheimer’s disease.